PRO Tips: First-Rate Guidance for Second-Line Therapy After Tumor Necrosis Factor-Alpha Exposure in Patients with Crohn's Disease

Dig Dis Sci. 2023 Aug;68(8):3211-3212. doi: 10.1007/s10620-023-07941-1. Epub 2023 May 5.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Crohn Disease* / diagnosis
  • Crohn Disease* / drug therapy
  • Humans
  • Infliximab
  • Tumor Necrosis Factor-alpha

Substances

  • Tumor Necrosis Factor-alpha
  • Infliximab